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Abstract 
Solid dispersions are efficient means for improving the dissolution rate of hydrophobic drugs. In this study ternary solid 
dispersions were made by melting method using PEG 6000, three types of sugar esters and three enolic acid derivates used as 
non-steroidal anti-inflammatory drugs piroxicam, meloxicam and tenoxicam. The prepared solid dispersions were 
characterized by X-ray diffraction. Dissolution studies, kinetic calculations, and in the case of tenoxicam permeability and 
toxicity studies on Caco-2 human intestinal epithelial cells were also performed. X-ray diffraction studies showed a 
significant decrease in the degree of crystallinity due to amorphisation of the active ingredient or formation of a solid 
solution. The highest amount of drug dissolution in artificial gastric juice was obtained in the presence of 5% sugar esters. In 
the case of piroxicam and meloxicam the kinetics of dissolution were modified by the studied excipients. PEG 6000 did not 
change the toxicity of tenoxicam, while stearate and palmitate sucrose esters increased the damage to cultured Caco-2 cells. 
Laurate sucrose ester was the least toxic. The excipients did not modify the permeability of the lipid soluble tenoxicam across 
epithelial cells. Sucrose esters significantly increased the dissolution of model drugs, and may reduce the interindividual 
differences observed in the absorption rate of these drugs, due to their poor solubility. 
 
Rezumat 
Utilizarea dispersiilor solide este o metodă eficientă de creştere a vitezei de dizolvare a substanţelor hidrofobe. În cadrul 
acestui studiu s-au preparat dispersii solide ternare utilizând PEG 6000, trei tipuri de esteri ai zaharozei şi trei reprezentanţi 
din clasa acizilor enolici utilizaţi ca antiinflamatoare nesteroidiene (piroxicam, meloxicam, tenoxicam). Produşii preparaţi au 
fost analizaţi prin metoda difracţiei de raze X. S-au efectuat testele de dizolvare, calcule cinetice şi în cazul tenoxicamului 
studii de permeabilitate şi toxicitate pe celule Caco-2. Difractogramele arată scăderea gradului relativ de cristalinitate datorită 
amorfizării substanţei active sau formării unei soluţii solide. Testele de dizolvare arată că în suc gastric artificial cantitatea 
cea mai mare de substanţă activă se dizolvă din produşii cu conţinut de 5% în esteri ai zaharozei. În cazul piroxicamului şi 
meloxicamului s-a modificat cinetica dizolvării în prezenţa substanţelor auxiliare studiate. Studiile de toxicitate pe celulele 
Caco-2 au arătat că PEG 6000 nu influenţează toxicitatea tenoxicamului, pe când stearatul de zaharoză şi palmitatul de 
zaharoză o cresc. Lauratul de zaharoză este cel mai puţin toxic. Permeabilitatea tenoxicamului  prin celule epiteliale nu a fost 
modificată semnificativ de către substanţele auxiliare. Esterii zaharozei cresc solubilitatea substanţelor dizolvate, putând 
astfel să scadă diferenţele interindividuale apărute în rata de absorbţie. 
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Introduction 
The use of solid dispersions (SD), hydrophobic 
drugs dispersed in an inert hydrophilic matrix in 
solid state, is an effective method to increase 
lipophilic drugs’ water solubility and dissolution 
rate [1, 4, 11, 24]. 
The most frequently used hydrophilic carriers are 
polyethylene glycols (PEGs), polyvinylpyrrolidone 
and cellulose derivatives, like hydroxypropyl-
methylcellulose, hydroxypropylcellulose, or hydroxyl-
propylmethylcellulose phthalate [11]. Some of 
these polymers have low melting points and high 
water solubility therefore, generally the two major 
processes of preparing SDs are the melting method 
and the solvent evaporation method [11, 20]. 
Regardless of the preparation methodology the 
structure of the SD is hard to clarify. Most 
frequently amorphisation of drug occurs or solid 
solutions are formed [3]. Recently it was demonstrated 
that using a carrier with surface activity or a 
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mixture of an amorphous polymer and a surfactant 
the dissolution profile can be improved [8, 11, 20]. 
Among the used surfactants in solid (lipid) 
dispersions, increasing use of sugar esters (SE) can 
be observed [6, 7, 17]. Sugar esters are nonionic 
surfactants consisting of sucrose as hydrophilic 
group and fatty acids as lipophylic groups [26]. It 
was demonstrated by Szűts et al. that these 
auxiliary substances, with low melting points 
between 47-79°C and heat-stability, can be used in 
solid dispersion made by melting method [18]. 
Three types of sugar esters, laurate, palmitate and 
stearate with hydrophilic-lipophilic balance (HLB) 
values of 16 were studied. The carrier was PEG 6000, 
a widely used high molecular weight polymer, which 
was described to improve solubility and dissolution 
property of drugs in the presence of SDs [9, 13, 21]. 
Three representative enolic acid (oxicam) derivates 
belonging to non-steroidal anti-inflammatory drugs 
(NSAIDs) were chosen as active pharmaceutical 
ingredients (API): piroxicam (PX), meloxicam 
(MX) and tenoxicam (TX) (Table I). These drugs 
belong to Class II of the Biopharmaceutical 
Classification System, which means low aqueous 
solubility and high permeability [12, 22]. Oxicams 
are characterized by the 4-hydroxybenzothiazine 
heterocycle, and are weak acid with pKa value 
about 5.3-6.3 [14]. Despite their high lipophilicity 
and permeability (they have a rapid and almost 
complete absorption) a delayed onset of anti-
inflammatory and analgesic effect can be observed 
due to their low dissolution in gastric and intestinal 
juice [2, 5]. 
Table I 
The chemical structures and the IUPAC names of the studied oxicams [25] 
Piroxicam Meloxicam Tenoxicam 
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4-Hydroxy-2-methyl-N-(2-pyridyl)-2H- 
1,2-benzothiazine-3-carboxamide-
1,1-dioxide 
4-Hydroxy-2-methyl-N-(5-methyl-2-
thiazolyl)-2H-1,2-benzothiazine-3-
carboxamide 1,1-dioxide 
4-Hydroxy-2-methyl-N-(2-pyridyl)-
2H-thieno[2,3-e][1,2]thiazine- 
3-carboxamide-1,1-dioxide. 
 
The aim of our study was to make binary and 
ternary solid dispersions with sugar ester content 
and to examine the role and the effect of a third 
component on the binary solid dispersion’s 
physico-chemical and dissolution properties. 
Besides solubility improvement, the further goal of 
our study was to investigate how API toxicity and 
permeability are affected in the solid dispersions 
using human Caco-2 intestinal epithelial cell monolayers. 
 
Materials and Methods 
Materials 
All reagents were purchased from Sigma-Aldrich 
Kft., Hungary, unless otherwise indicated. Laurate 
sucrose ester (D-1216) was of pharmaceutical 
grade, palmitate (P-1670) and stearate (S-1670) 
sucrose esters were of analytical grade (Mitsubishi 
Kagaku Foods Co., Japan). PEG 6000 was supplied 
form Merck KgaA, Germany. Piroxicam (PX) was 
obtained from Nantong Jinghua Pharmaceutical, 
China; meloxicam (MX) from Sun Pharma Ltd, 
India and tenoxicam (TX) from Nantong Chemding 
Chephar, China. All other reagents and solvents 
were of analytical grade. 
 
Preparation of solid dispersions 
Solid dispersions were made with PX, MX, and 
TX, containing PEG 6000 and 5% or 10% of one of 
the three sugar ester derivates. The active ingredient 
weight ratio in the products was 10%. The 
composition of the products is presented in Table II. 
Binary solid dispersions, blank formulations, 
containing API and PEG 6000 were also made. 
Solid dispersions were prepared by the melting 
method. PEG 6000 was melted at 80 °C, and then 
the SE was added to the melted PEG and dissolved 
under continuous stirring, while increasing the 
temperature to 100 °C. The P1670 and S1670 
weren’t dissolved in the melted PEG, therefore 
these SEs were suspended in a small amount of 
ethanol, then added to the PEG 6000. The mixture 
was blended until ethanol evaporation. Accurately 
measured API was added to the melted mixture and 
stirred for 20 min. The obtained mixture was 
poured in a thin layer on the cooled plate of a 
Julabo F-32 refrigerated and heating circulator 
(JULABO Labortechnik GmbH, Germany) for a 
quick freeze. The solidified mass was ground 
gently with a mortar and pestle and passed through 
a 100 µm sieve. The products were stored at room-
temperature until investigations. 
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Table II 
Composition of the solid dispersions 
No. API (%) SE (%) Product (abbreviation) Mention 
1 
PX 10 
D1216 5% PX:D5 
PX dissolves in the melted PEG 
6000-SE mixture 
2 10% PX:D10 
3 P1670 5% PX:P5 4 10% PX:P10 
5 S1670 5% PX:S5 6 10% PX:S10 
7 
MX 10 
D1216 5% MX:D5 
MX and TX don’t dissolve in 
the melted PEG 6000-SE 
mixture (a suspension is formed)  
 
8 10% MX:D10 
9 P1670 5% MX:P5 10 10% MX:P10 
11 S1670 5% MX:S5 12 10% MX:S10 
13 
TX 10 
D1216 5% TX:D5 14 10% TX:D10 
15 P1670 5% TX:P5 16 10% TX:P10 
17 S1670 5% TX:S5 18 10% TX:S10 
19 PX/MX/TX 10 0 0 blank product  
Abbreviations: API, active pharmaceutical ingredient; D1216, laurate sucrose ester; MX, meloxicam; S1670, stearate sucrose 
ester; SE, sugar ester; P1670, palmitate sucrose ester; PX, piroxicam; TX, tenoxicam. 
 
X-ray powder diffractometry (XRD) 
State of oxicams in solid dispersions were 
characterized by X-ray powder diffraction, using 
Rigaku MiniFlexTM II X-Ray Diffractometer 
(Rigaku Co. Tokyo, Japan), where the tube anode 
was Cu with Kα=1.5405 Ǻ. The pattern was 
collected with 30 kV of tube voltage and 15 mA of 
tube current in step scan mode (4°/min). The 
instrument was calibrated using silicon. In order to 
check the stability of the SDs the analyses were 
repeated after 3 months. 
In vitro dissolution studies and kinetic calculations 
The dissolution of the active ingredients and the 
solid dispersions was determined using a paddle 
apparatus (Pharma Test PTW-II, Germany). The 
dissolution media consisted of 100 mL artificial 
gastric juice without pepsin (AGJ, pH=1.2, 
according to the European Pharmacopoeia 7.0) and 
100 mL artificial intestinal juice without pancreatin 
(AIJ, pH=6.8). Samples of API and solid 
dispersions corresponding to 30 mg active 
ingredient were put in hard gelatin capsules and 
added to the dissolution medium at a rotation speed 
of 100 rpm and a temperature of 37 °C. Aliquots of 
5 mL were withdrawn and filtered at 5, 10, 15, 30, 
60, 90 and 120 min, and replaced with the same 
volume of fresh dissolution medium. The amount 
of API was determined spectrophotometrically 
(ATI UNICAM UV-VIS Spectrophotometer, USA) 
at the corresponding wavelength (in AGJ at 336 
nm, 348 nm and 364 nm; in AIJ at 360 nm, 368 and 
372 nm for PX, MX and TX, respectively). The 
measurements were performed in triplicate. In AGJ 
non-sink condition was applied in order to evaluate 
the supersaturation phenomenon. The mechanism 
of drug release was assessed with different 
mathematical models (First order kinetics with Tlag, 
Higuchi, Hixson-Crowell, Korsmeyer-Peppas, 
Logistic, Gompertz and Weibull) using DDSolver 
software. The best fit was chosen based on the 
correlation coefficient (Table III). 
Table III 
Mathematical functions which describe the studied formulations’ dissolution profile 
Function Formula Parameters 
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α - scale factor 
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α - scale factor 
β - shape factor 
Korsmeyer-
Peppas 
n
lagp ttkKF )( −=  
kKp - release constant incorporating structural and geometric 
characteristics of the drug-dosage form 
n - diffusional exponent indicating the drug-release mechanism 
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Cell culture 
Human Caco-2 intestinal epithelial cells (ATCC 
cat. no. HTB-37) were grown in Eagle’s minimal 
essential medium (MEM; Gibco, Invitrogen, USA) 
supplemented with 10 % fetal bovine serum 
(Lonza, Switzerland), sodium-pyruvate (Gibco, 
Invitrogen, USA), and 50 µg/mL gentamicin in a 
humidified incubator with 5 % CO2 at 37 °C. Cells 
were seeded to rat tail collagen (0.05 %) coated 
culture dishes at a density of 5 × 104 cells/cm2 and 
the medium was changed every 2 days. When cells 
reached approximately 80-90 % confluency in the 
dish they were subcultured with 0.05 % trypsin-
EDTA solution. For the cytotoxicity assays cells 
were cultured in 96-well plates in Dulbecco’s 
modified Eagle’s medium without phenol red 
(DMEM; Gibco, Invitrogen, USA), supplemented 
similarly to MEM. For permeability studies Caco-2 
cells were cultured on Transwell filter inserts 
(polycarbonate membrane, 0.4 µm pore size, 1.12 
cm2 surface area, Corning Costar Co., Lowell, MA, 
USA) for 21 days. All surfaces were coated with 
0.05 % rat tail collagen before cell seeding. 
Measurement of the cellular toxicity of the 
formulations 
Caco-2 cells were grown in 96-well plates (Orange, 
UK) for 4 days until reaching confluency and were 
used for experiments. For each treatment group 4-8 
parallel wells were used and during treatment 
period plates were placed on a horizontal shaker at 
100 rpm. Stock solutions were prepared from each 
investigated samples in DMEM containing TX at 
3000 µg/mL concentration. Working solutions were 
diluted from stock solutions and for each sample 
seven concentrations were prepared which 
contained tenoxicam at the following doses 1, 10, 
30, 100, 300, 1000, 3000 µg/mL. 
The release of the cytoplasmatic enzyme lactate 
dehydrogenase (LDH) from cells is a sign of cell 
membrane damage and can be used as an indicator 
of cell death. LDH from culture supernatant was 
determined by a commercially available 
cytotoxicity detection kit measuring LDH release 
(Roche, Switzerland). After treatments with the 
formulations for 24 h 50 µL samples from culture 
supernatants were incubated with equal amounts of 
reaction mixture for 15 minutes at room 
temperature. The enzyme reaction was stopped by 
addition of 0.1 M HCl. Absorbance was measured 
at a wavelength of 492 nm with a microplate reader 
(Fluostar Optima, BMG Labtechnologies, 
Germany). Cytotoxicity was calculated as 
percentage of the total LDH release from cells 
treated by 1 % Triton X-100 detergent. 
Living cells convert the yellow dye 3-(4,5-
dimethyltiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) to purple, insoluble formazan 
crystals. Caco-2 cells cultured in 96-well plates 
were treated for 24 h then incubated with 0.5 
mg / mL MTT solution for 3 hours in a CO2 
incubator. The amount of formazan crystals 
converted by the cells was dissolved in dimethyl-
sulfoxide and determined by measuring absorbance 
at 595 nm with a microplate reader (Fluostar 
Optima, BMG Labtechnologies, Germany). Results 
are shown as percentage of the viability of the 
control group. 
Transepithelial electrical resistance measurement 
Transepithelial electrical resistance (TEER) 
represents the permeability of tight intercellular 
junctions for ions. TEER was measured by an 
EVOM resistance meter (World Precision 
Instruments, USA) using STX-2 electrodes and it 
was expressed relative to the surface area of the 
epithelial monolayer (Ω × cm2). The TEERs of cell-
free inserts (100–120 Ω × cm2) were subtracted 
from each value. The TEER of Caco-2 human 
epithelial cell monolayers varied between 450 and 
600 Ω × cm2, and reached sufficient tightness to 
perform permeability studies. 
Permeability assay 
For drug permeability measurement Caco-2 
epithelial cells were seeded on Transwell filter 
inserts and cultured for 21 days to let the cells 
differentiate and develop tight intercellular 
junctions, reflected by high TEER values. TX 
permeability was measured using the different 
formulations (tenoxicam, binary solid dispersion 
and ternary products). Stock solutions and working 
solutions were prepared in Ringer-Hepes buffer 
(118 mM NaCl, 4.8 mM KCl, 2.5 mM CaCl2, 
1.2 mM MgSO4, 5.5 mM D-glucose, 20 mM Hepes, 
pH 7.4) and the final concentration of TX was 
3 µg/mL in each sample. Cell culture inserts were 
transferred to 12-well plates containing 1.5 mL 
Ringer-Hepes solutions in the lower, basolateral 
compartments. In upper, apical chambers culture 
medium was replaced by 500 µL working solutions 
containing sample dilutions in Ringer-Hepes. After 
1 hour incubation samples were collected from the 
upper and lower compartments and stored at -20 °C 
until measurement. 
The concentrations of the active ingredients in 
samples were determined by HPLC. A Merck 
HPLC system (consisted of quaternary pump L-
7100, auto sampler L-7200, column thermostat L-
7360, DAD detector L-7455, interface L-7000, 
solvent degasser L-7612, HSM manager software) 
was used. The analysis was carried out on ambient 
temperature using a Lichrospher RP select B C18 (5 
µm, 250 x 4.6, Merck, Germany) column. 
Determinations were performed by isocratic elution 
with a flow rate 2 mL/min. The mobile phase 
composition was 20 mM phosphate buffer and 
ACN (55:45) at pH 3.18. Volumes of 100 µL were 
injected using the loop method; the acetonitrile 
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detection wavelength was 372 nm. Calculations 
were performed by the measurement of peak areas. 
The apparent permeability was calculated using the 
formula: 
0CA
dt
dQ
Papp ⋅
=
, 
where dQ/dt is the rate of permeation of the drug 
across the cells, C0 is the donor compartment 
concentration at time zero and A is the area of the 
cell monolayer. 
All data presented are means ± S.D. The values 
were compared using the analysis of variance 
followed by Dunnett tests using GraphPad Prism 
5.0 software (GraphPad Software Inc., USA). 
Changes were considered statistically significant at 
p < 0.05. All experiments were repeated at least two 
times, the number of parallel samples varied 
between 3 and 8. 
 
 
Results and Discussion 
X-ray powder diffractometry (XRD) 
XRD patterns of the APIs, auxiliary substances and 
their SDs are presented in Figure 1. In the case of 
PEG 6000 the two characteristic broad peaks can be 
observed at 2 Teta (2Θ) of 19.20° and 23.34°. The 
diffraction spectrum of P1670 sugar ester shows 
one broad peak with lowest intensity at 21.36°. 
XRD patterns of pure APIs show sharp, intense 
peaks according to their crystalline status. 
Characteristic peak positions for MX are 15.06° 
and 16.06°, for PX are at 8.57°, 17.6° and 27.32° 
and for TX at 10.94°, 16.02°, 23.36° and 29.34°. In 
the case of all three SDs the characteristic peaks for 
crystalline APIs and for P1670 are not present, only 
the two broad peaks for PEG 6000 can be observed. 
This can be explained by the amorphisation of APIs 
in SDs or the formation of solid solution. The peaks 
associated to the PEG 6000 are not shifted 
significantly, so it can be assumed that there are no 
interactions between APIs and auxiliary substances. 
 
 
Figure 1. 
XRD patterns of PX, MX, TX, PEG 6000, P1670 and SDs  
Abbreviations: MX, meloxicam; P1670, palmitate sucrose ester; PX, piroxicam; TX, tenoxicam. 
 
The relative degree of crystallinity (RDC) was 
calculated by using this formula [16]: 
API
SD
I
IRDC =
, 
where ISD is the height of the SDs and IAPI is the 
height of the pure API at the same angle. The 2Θ 
grade for RDC was chosen to not interfere the API 
with the auxiliary substances. According to this 
criterion the following angles were chosen: 8.57° 
for PX, 15.06° for MX and 11.5° for TX. The RDC 
values for all three types of SE and in all three APIs 
were below 0.16, and can be arranged in the 
following order: MX>TX>PX. 
In order to verify the stability of the SDs, the 
analyses were repeated after 3 months. Similar 
results to those shown in Figure 1 were obtained, 
which indicates that SDs are stable if stored at room 
temperature. 
Dissolution studies 
Dissolution profiles in AGJ and AIJ are presented 
in Figure 2. 
The best dissolution result was obtained in the case 
of PX in AGJ by the SD containing 5% P1670, 
after 120 min 1.68 times more PX was dissolved 
from the formulation. The efficacy of sucrose esters 
to increase the dissolution of PX was in the 
following order: P1670>S1670>D1216. In the case 
of all three SEs, compounds containing only 5% SE 
increase better the solubility compared to those 
with 10% SE. 
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Figure 2. 
Dissolution profiles of oxicams alone and in solid dispersions measured in artificial gastric juice (AGJ) and 
artificial intestinal juice (AIJ). 
Abbreviations: D1216, laurate sucrose ester; MX, meloxicam; S1670, stearate sucrose ester; P1670, palmitate sucrose ester; PX, piroxicam; 
TX, tenoxicam. 
 
In the AIJ 84.6% of PX dissolves and the auxiliary 
substances does not modify significantly the 
dissolved amount of PX. In this case also the best 
result was obtained by the product containing 5 % 
P1670. Based on the coefficient correlation (R) 
criteria, the mathematic model to describe 
optimally the dissolution profile of PX’s SDs is the 
Logistic-model in both dissolution media. The used 
auxiliary substances modified the PX’s dissolution 
kinetics because the pure PX release profile is 
described in AGJ by Korsmeyer-Peppas function 
and in AIJ by Gompertz function [23]. For the pure 
PX and each formulation the R values were above 
0.99. Obviously we can part the dissolution profiles 
in two stages: before 30 minutes, characterized by 
the α-scale factor, which refers to the starting rate 
of dissolution depending on wettability; and after 
30 minutes characterized by the β-shape factor 
showing the rate of dissolution in the second stage. 
In AGJ PX:S5 and PX:D10 products begin to 
dissolve faster according to the α-parameter. In 
each case the β-shape factor increases compared to 
PX, which means that the rate of dissolution is 
higher in the SDs (Tables IV and V). According to 
the shape-factor, the PX:P10 product presents the 
fastest dissolution. In AIJ similar to the results 
obtained in the AGJ, the products PX:S5 and 
PX:D10 exhibit the fastest starting dissolution. It 
can be seen that PX and products without SE have 
the lowest α-values, due to the poorest wettability 
compared to products containing a surfactant. 
In the case of MX the dissolved amount in AGJ 
increases 5 times in the case of SD containing 5 % 
D1216 after 120 minutes (2 % dissolves from the 
total amount compared to MX from which no more 
than 0.11 % dissolves). In each case, except MX, 
the blank formulation and the MX:D5 product, on 
the dissolution profiles the supersaturation 
phenomena could be observed with a peak on the 
dissolution curves at 5-10 minutes. It can be 
hypothesized that the amorphous active ingredient 
solubility increased first followed by the 
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recrystallization and solubility reduction. In AIJ for 
the pure API the Korsmeyer-Peppas model 
describes the dissolution profile, which is modified 
in the presence of auxiliary substances, products for 
which the drug release kinetics correspond best to 
the Gompertz’s model. In AIJ the MX:D5, 
MX:D10 and MX:P5 products exhibit the fastest 
solubility in the first stage. From the product 
containing 5% S1670 about 3 times more MX 
dissolves after 120 min (52.33% vs 17.60%) and in 
this case the rate of dissolution in the second stage 
is also the highest (Table V). 
Table IV 
Dissolution kinetic calculation results in AGJ 
API PX TX 
Kinetic Model Logistic Gompertz 
Parameters α ± SD β ± SD α ± SD β ± SD 
Pure API -3.37 ± 0.89 2.73 ± 1.41 3.91 ± 1.31 1.71 ± 0.33 
D5 -4.74 ± 0.21 3.05 ± 0.29 8.38 ± 4.07 3.39 ± 0.58 
D10 -3.34 ± 0.03 3.74 ± 0.29 6.48 ± 0.72 2.96 ± 0.20 
P5 -5.66 ± 0.22 4.79 ± 0.24 12.05 ± 5.87 2.66 ± 0.52 
P10 -5.46 ± 1.10 4.89 ± 0.75 13.24 ± 2.76 3.04 ± 0.03 
S5 -4.04 ± 0.04 3.94 ± 0.18 3.73 ± 1.75 2.07 ± 0.21 
S10 -4.14 ± 0.83 2.99 ± 0.56 6.31 ± 1.28 2.08 ± 0.17 
PEG 6000 -5.51 ± 0.18 4.28 ± 0.19 31.02 ± 9.48 3.86 ± 0.48 
Kinetic Model Korsmeyer-Peppas Gompertz 
Parameters kKp ± SD n ± SD α ± SD β ± SD 
Pure API 12.60 ± 3.53 0.25 ± 0.05 3.91 ± 1.31 1.71 ± 0.33 
Correlation coefficient R = 0.995 R = 0.998 
Abbreviations: API, active pharmaceutical ingredient; D, laurate sucrose ester; S, stearate sucrose ester; P, palmitate sucrose ester; PX, 
piroxicam; TX, tenoxicam. 
Table V 
Dissolution kinetic calculation results of SDs in AIJ 
API PX MX TX 
Kinetic model Logistic Gompertz Gompertz 
Parameters α ± SD β ± SD α ± SD β ± SD α ± SD β ± SD 
Pure API -8.23 ± 2.65 4.96 ± 1.59 26.33 ± 21.91 0.91 ± 0.66 7.41 ± 2.15 4.24 ± 1.68 
D5 -7.49 ± 1.17 4.89 ± 1.08 11.50 ± 10.95 1.55 ± 0.58 7.62 ± 4.39 2.37 ± 0.94 
D10 -5.13 ± 0.48 4.38 ± 0.27 8.66 ± 1.68 0.67 ± 0.35 9.34 ± 2.01 2.51 ± 0.15 
P5 -8.14 ± 0.37 5.79 ± 0.45 9.11 ± 1.57 1.68 ± 0.21 7.47 ± 1.09 1.91 ± 0.38 
P10 -7.24 ± 0.58 4.91 ± 0.67 18.96 ± 13.92 1.73 ± 0.53 10.60 ± 3.18 1.96 ± 0.35 
S5 -5.55 ± 0.90 4.29 ± 0.47 17.71 ± 10.57 1.92 ± 0.63 6.87 ± 2.01 1.74 ± 0.48 
S10 -7.66 ± 0.48 5.20 ± 0.28 7.41 ± 0.61 1.32 ± 0.06 9.90 ± 2.34 1.66 ± 0.06 
PEG 6000 -9.97 ± 2.63 6.53 ± 1.72 25.74 ± 22.3 2.39 ± 0.46 43.10 ± 19.65 3.03 ± 0.23 
Kinetic model Gompertz Korsmeyer-Peppas Gompertz 
Parameters α ± SD β ± SD kKp ± SD n ± SD α ± SD β ± SD 
Pure API 187.19 ± 289.2 2.53 ± 1.22 0.18 ± 0.12 1.01 ± 0.21 635.7 ± 815.4 4.24 ± 1.68 
Correlation coefficient R = 0.9997 R = 0.9996 R = 0.998 
Abbreviations: API, active pharmaceutical ingredient; D, laurate sucrose ester; S, stearate sucrose ester; P, palmitate sucrose ester; PX, 
piroxicam; TX, tenoxicam. 
 
In the case of TX in AGJ according to the α-
parameter the drug and the TX:D10 and TX:S5 
products show the fastest dissolution in the initial 
phase. After 120 min 33.1% of PX dissolves, the 
best result was obtained in the case of PX:S5. 
According to the β-parameter the rate of dissolution 
in the second phase is the highest in the case of 
blank formulation and TX:D5. In AIJ the TX:D5 
and the TX:S5 products exhibit the fastest 
dissolution in the starting phase, and the TX and the 
blank product in the second phase. After 120 min 
the total amount of TX was dissolved from the 
products containing 5% P1670 and S1670 (Tables 
IV and V). 
Cellular toxicity of formulations containing sucrose 
esters 
Comparing the effect of tenoxicam and TX 
containing formulations the active agent did not 
cause damage to Caco-2 human intestinal epithelial 
cells below 100 µg/mL concentration measured by 
MTT dye conversion and lactate dehydrogenase 
release assays, but a complete toxicity was 
registered at 3 mg/mL (Table VI). PEG 6000 did 
not change the toxicity pattern of the active 
ingredients. Among the formulations, those 
containing stearate sucrose ester S1670 showed the 
highest toxicity, which was increased ten times as 
compared to TX and to formulations containing 
PEG 6000. Palmitate sucrose ester P-1670 
FARMACIA, 2015, Vol. 63, 2 
 293 
containing samples were less toxic than 
formulations with stearate sucrose ester. 
Formulations containing both TX and P1670 
showed similar toxicity, except the concentrations 
causing 100% cell death, which was higher, 
probably due to the less toxic TX. The best 
formulations for TX were those containing laurate 
sucrose ester D1216. The non-toxic doses were 
similar in the case of the active ingredients with or 
without PEG 6000 (Table VI). 
It should be noted that sucrose esters are 
hydrolysed in the gastrointestinal tract and were 
found non-toxic in animal studies as reviewed 
recently [19]. Therefore toxicity measurements of 
the products on cultured cells may not mimic 
exactly the in vivo biological effects. 
Table VI 
Cellular toxicity of TX, PEG 6000 and TX containing SDs 
Excipients MTT dye conversion LDH release 
 TC0 (µg/ml) TC100 (µg/ml) TC0 (µg/ml) TC100 (µg/ml) 
TX 100 >3000 1000 >3000 
TX:D5 100 1000 100 >1000 
TX:D10 100 300 100 300 
TX:P5 30 300 10 300 
TX:P10 30 100 30 300 
TX:S5 30 300 10 300 
TX:S10 10 100 10 100 
PEG 6000 100 >3000 1000 >3000 
Abbreviations: D, laurate sucrose ester; LDH, lactate dehydrogenase; S, stearate sucrose ester; P, palmitate sucrose ester; TC0, highest non-
toxic concentration; TC100, lowest concentration killing all cells; TX, tenoxicam. 
 
 
Figure 3. 
A 1-hour permeability assay for TX and SDs on Caco-2 epithelial cell layers. 
Abbreviations: D, laurate sucrose ester; LDH, lactate dehydrogenase; S, stearate sucrose ester; P, palmitate sucrose ester; Papp, apparent 
permeability coefficient; TEER, transepithelial electrical resistance; TX, tenoxicam. 
 
Effect of formulations on transepithelial electrical 
resistance in Caco-2 cells 
The Caco-2 cell layer resistance was about 450-600 
Ω × cm2. Cells were treated by dilution of the 
samples containing 3 µg/mL (Figure 3A) or 100 
µg/mL (Figure 3C) active ingredients. After 1 hour 
treatment no significant differences were found in 
the resistance of cell monolayers between treatment 
groups at the lower concentrations. At the higher 
dose of samples a decrease of resistance was seen 
indicating the opening of the junctions connecting 
Caco-2 epithelial cells (Figure 3C). A similar effect 
was seen on RPMI2650 nasal epithelial cells treated 
with comparable concentrations of laurate sucrose 
ester [10]. 
Measurement of tenoxicam permeability across 
Caco-2 cell layers 
Toxicity measurements showed that TX in doses 
lower than 100 µg/mL did not cause cell damage. 
Addition of PEG 6000 did not change toxicity 
when measured by MTT dye conversion assay; 
LDH release measurement indicated a slight 
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difference in the case of TX. The presence of 
sucrose esters especially the palmitate and stearate 
increased toxicity. 
Using 3 µg/mL solutions the permeability 
coefficient of TX was high reflecting its lipophilic 
characteristics. PEG 6000 and sucrose esters could 
not further increase the permeability of TX at the 
lowest concentration tested, when already the active 
ingredients were completely solubilized (Fig. 3). 
The analysis was repeated in the case of TX, the 
blank product containing only API and PEG, and 
TX:D5 and TX:D10 products using 100 µg/mL 
suspensions. Similarly to the first set of 
experiments, no change in TX permeability was 
seen (Figure 3D). 
 
Conclusions 
The aim of this study was to investigate the role of 
sugar esters on the physico-chemical properties of 
PEG-based solid dispersions containing oxicams. 
Products were prepared using the melting method 
and tested by X-ray powder diffraction analysis, in 
vitro dissolution studies; kinetic calculations and 
permeability examinations. X-ray diffraction 
patterns indicated that crystalline APIs aren’t 
present in SDs due to amorphisation of APIs or 
solid solution formation. Analyses repeated after 3 
months showed the same results, proving that the 
products are stable. In the case of PX in both used 
dissolution media the best results were obtained 
with 5% P1670 containing products. In AGJ the 5% 
D1216 containing product increased five times the 
amount of dissolved MX. In AIJ the MX:S5 proved 
to be the most efficient, enhancing three times the 
dissolved amount. The dissolution kinetics of PX 
and MX in AGJ is modified in the presence of 
auxiliary substances. A similar phenomenon was 
observed in the case of ampicillin decomposition in 
the presence of β-cyclodextrin [15]. The cellular 
toxicity studies showed that TX causes no damage 
to the Caco-2 human epithelial cells. Among the 
SEs the S1670 showed the highest toxicity followed 
by P1670. Laurate sucrose ester D1216 was the 
least toxic among the tested excipients in 
formulations and showed the smallest additional 
toxic effect beside PEG 6000 and drugs. That result 
was similar to the work of Szűts et al. when D1216 
toxicity was investigated on Caco-2 cells and no 
toxic effect was observed at comparable 
concentrations when tested alone [17]. The 
resistance of cell monolayers was only increased at 
higher SE concentrations. The permeability 
coefficients for the lipophilic TX were high, and 
not altered by the presence of excipients. 
It can be concluded that the studied formulations 
improve the biopharmaceutical properties of these 
oxicams. Sucrose esters significantly increased the 
studied oxicams’ dissolution in artificial gastric and 
intestinal juice, and may reduce the interindividual 
differences observed in the absorption rate of these 
drugs, due to their poor solubility. 
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